Researchers suggested that the reduction of drug spending by using value-based clinical pathways to optimize chemotherapy utilization is possible and can increase the chances of a practice’s success within the Oncology Care Model.
Prostate-specific membrane antigen PET/CT was found to be a suitable replacement for conventional imaging in patients with prostate cancer, providing superior accuracy to the combined findings of CT and bone scanning.
These projections suggest that premature and sudden lifting of interventions put in place could lead to an earlier secondary peak of COVID-19, which could be flattened by relaxing the interventions gradually.
Researchers reported on the incidence and outcomes of the SARS-CoV-2 infection, which has been linked to COVID-19, in patients with cancer who were treated at a tertiary cancer institution in Wuhan, China.
A study with a small sample size revealed that trastuzumab deruxtecan showed promising activity in multiple HER2-expressing or HER2-mutant solid tumors.
Favorable toxicity profiles and antitumor activity seen in this phase II study of pembrolizumab supports further evaluation of the drug in this patient population.
The European Society for Medical Oncology released key answers to questions about the coronavirus disease 2019 (COVID-19) as it pertains to cancer care.
The FDA has approved a phase III clinical trial to assess the safety and efficacy of intravenous tocilizumab (Actemra) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.
In this study, polypharmacy during the 6-month time period pre-IV chemotherapy was highly predictive of post-chemotherapy inpatient hospitalization.
This study examined the acquired resistance found from treatment with third-generation EGFR TKIs to see if it was associated with diverse pathways, with an eye for the EGFR T790M mutation.